Publication number: 20220242867
Abstract: The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. The compounds described herein are used as enhancers and/or modifiers of an immune response (e.g., innate and/or adaptive immune response), and are useful in treating and/or preventing a disease, as adjuvants in a vaccine for the disease, (e.g., proliferative disease, inflammatory disease, autoimmune disease, infectious disease, or chronic disease), or as stand alone anti-infective or immune response modifying agents. Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.
Type:
Application
Filed:
November 14, 2018
Publication date:
August 4, 2022
Applicants:
Dana-Farber Cancer Institute, Inc., Children's Medical Center Corporation
Inventors:
Ofer Levy, David J. Dowling, Francesco Borriello, David A. Scott, Spencer E. Brightman, Frederic Feru